Castle Biosciences, Inc.
CSTL
$38.63
$0.661.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.04M | 86.19M | 87.99M | 86.31M | 85.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.04M | 86.19M | 87.99M | 86.31M | 85.78M |
| Cost of Revenue | 18.70M | 17.63M | 16.38M | 16.18M | 15.61M |
| Gross Profit | 64.34M | 68.56M | 71.61M | 70.13M | 70.17M |
| SG&A Expenses | 55.91M | 58.07M | 58.62M | 49.97M | 50.50M |
| Depreciation & Amortization | 2.28M | 1.96M | 28.33M | 4.34M | 2.27M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.85M | 90.44M | 115.92M | 82.26M | 80.70M |
| Operating Income | -6.80M | -4.25M | -27.93M | 4.05M | 5.08M |
| Income Before Tax | -386.00K | -143.00K | -26.27M | 7.89M | 8.28M |
| Income Tax Expenses | 115.00K | -4.67M | -423.00K | -1.71M | 6.01M |
| Earnings from Continuing Operations | -501.00K | 4.52M | -25.85M | 9.59M | 2.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -501.00K | 4.52M | -25.85M | 9.59M | 2.27M |
| EBIT | -6.80M | -4.25M | -27.93M | 4.05M | 5.08M |
| EBITDA | -1.17M | -837.00K | 1.84M | 9.82M | 8.62M |
| EPS Basic | -0.02 | 0.16 | -0.90 | 0.34 | 0.08 |
| Normalized Basic EPS | -0.08 | -0.03 | -0.54 | 0.16 | 0.19 |
| EPS Diluted | -0.02 | 0.15 | -0.90 | 0.31 | 0.08 |
| Normalized Diluted EPS | -0.08 | -0.03 | -0.54 | 0.15 | 0.18 |
| Average Basic Shares Outstanding | 29.07M | 28.91M | 28.61M | 28.13M | 27.84M |
| Average Diluted Shares Outstanding | 29.07M | 29.55M | 28.61M | 30.20M | 29.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |